Sustained Monomorphic Ventricular Tachycardia: Immediate Evaluation and Management, Long-Term Management

Nasir N Jr, Taylor A, Doyle TK, et al. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol 1994;74:1183–1186. Ho DS, Zecchin RP, Richards DA, et al. Double blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994;344:18–23. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol 1996;27:67–75. Kowey PR, Levine JH, Herre JM, et al. Randomized, double blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. Circulation 1995;92:3255–3263. Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation 1995;92:3264–3272. Schwartzman D, Jadonath RL, Callans DJ, et al. Radiofrequency catheter ablation for control of frequent ventricular tachycardia with healed myocardial infarction. Am J Cardiol 1995;75:297–299. Kim SG. Evolution of the management of malignant ventricular tachyarrhythmias: The roles of drug therapy and implantable defibrillators. Am Heart J 1995;130:1144–1150. Josephson ME, Callans DJ: Sustained ventricular tachycardia. In Kastor JA (ed), Arrhythmias. W.B. Saunders Co., Philadelphia 1993; pp. 336–362. Callans DJ, Josephson ME. Ventricular tachycardias in the setting of coronary artery disease. In Zipes DP, Jalife J (eds), Cardiac Electrophysiology: From Cell to Bedside. 2nd edition. W.B. Saunders Company, Philadelphia, 1995; pp. 732–743. Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic sustained ventricular tachyarrhythmias. N Engl J Med 1992;327:987–992. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. Am J Cardiol 1993;72:820–827. Mason JW, for the ESVEM Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug therapy efficacy for ventricular tachyarrhythmias. N Engl J Med 1993;329:445–451. Siebels J, Kuck KH. Implantable cardioverter-defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139–1144. Link MS, Homoud M, Foote CB, et al. Antiarrhythmic drug therapy for ventricular arrhythmias: Current perspectives. J Cardiovasc Electrophys 1996;7:653–670. Sarter BH, Finkle JK, Gerszten RE, Buxton AE. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 1996;28:122–129. Bocker D, Block M, Isbruch F, et al. Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J 1995;73:158–163. Bardy GH, Hofer B, Johnson G, et al. Implantable transvenous cardioverter-defibrillators. Circulation 1993;87:1152–1168. Zipes DP, Roberts D. Results of the international study of the implantable pacemaker cardioverter-defibrillator. A comparison of epicardial and endocardial lead systems. Circulation 1995;92:59–65.